In it for the promise to change the cancer treatment landscape.
Todd brings extensive financial leadership experience, most notably at public biotechnology companies, to Seagen. Leveraging this expertise, he has positioned our finance, investor relations, communications and facilities teams to support the company’s mission and continued growth.
Prior to joining Seagen, Todd was the Vice President of Finance and Administration and Chief Financial Officer at both Targeted Genetics and Aastrom Biosciences (now Vericel Corporation). He also held positions at Integra LifeSciences Corporation and Telios Pharmaceuticals, Inc. Todd began his career at Ernst & Young LLP in the life sciences and technology practices.
Todd holds a B.S. in Accounting and Computer Science from Oregon State University. He is also the Chairman of the Board for Neoleukin Therapeutics, Inc.